These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28049213)

  • 1. Dystrophic calcification after palliative chemotherapy in a patient with renal cell carcinoma.
    Lim DH; Lee SI; Park KW
    Korean J Intern Med; 2017 Mar; 32(2):380-381. PubMed ID: 28049213
    [No Abstract]   [Full Text] [Related]  

  • 2. Temsirolimus (Torisel) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
    [No Abstract]   [Full Text] [Related]  

  • 3. Potential role of everolimus in inducing cholestasis.
    Pantano F; Santini D; Guida F; Vincenzi B; Tonini G
    Ann Oncol; 2010 Feb; 21(2):433. PubMed ID: 19955336
    [No Abstract]   [Full Text] [Related]  

  • 4. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
    Ali SM; Stephens PJ; Miller VA; Ross JS; Pal SK
    Eur Urol; 2015 Aug; 68(2):341-3. PubMed ID: 25796537
    [No Abstract]   [Full Text] [Related]  

  • 5. Temsirolimus in the treatment of advanced renal cell carcinoma.
    Gore ME
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix87-8. PubMed ID: 17631601
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of mTOR inhibitor side effects.
    Creel PA
    Clin J Oncol Nurs; 2009 Dec; 13 Suppl():19-23. PubMed ID: 19948456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In brief: Cabozantinib (Cabometyx) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2016 Jul; 58(1499):e97. PubMed ID: 27403787
    [No Abstract]   [Full Text] [Related]  

  • 8. [ASCO 2006: temsirolimus increases survival].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):12. PubMed ID: 23646393
    [No Abstract]   [Full Text] [Related]  

  • 9. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.
    De Masson A; Fouchard N; Méry-Bossard L; Dauendorffer JN
    Dermatology; 2011; 223(1):4-8. PubMed ID: 21846963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus.
    Cetin B; Coskun U; Yildiz R; Buyukberber S; Baykara M; Benekli M
    J Oncol Pharm Pract; 2011 Sep; 17(3):274-8. PubMed ID: 20215482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temsirolimus in metastatic renal cell carcinoma.
    Négrier S
    Ann Oncol; 2008 Aug; 19(8):1369-1370. PubMed ID: 18504249
    [No Abstract]   [Full Text] [Related]  

  • 12. Everolimus in renal cell carcinoma.
    Wang Y
    Drugs Today (Barc); 2010 Aug; 46(8):557-66. PubMed ID: 20830316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyoderma gangrenosum with the use of sunitinib.
    Nadauld LD; Miller MB; Srinivas S
    J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
    [No Abstract]   [Full Text] [Related]  

  • 14. Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma.
    Mizuno R; Asano K; Mikami S; Nagata H; Kaneko G; Oya M
    Jpn J Clin Oncol; 2012 May; 42(5):442-6. PubMed ID: 22438405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three new drugs available to fight kidney cancer.
    Bankhead C
    J Natl Cancer Inst; 2006 Sep; 98(17):1181-2. PubMed ID: 16954469
    [No Abstract]   [Full Text] [Related]  

  • 16. Lingual angioedema associated with everolimus.
    Mackenzie M; Wood LA
    Acta Oncol; 2010; 49(1):107-9. PubMed ID: 20100146
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety profile of temsirolimus in patients with metastatic renal cell carcinoma.
    Levakov I; Vojinov S; Marusic G; Popov M; Levakov O; Popov M; Jeremic D
    J BUON; 2016; 21(6):1442-1448. PubMed ID: 28039705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian target of rapamycin (mTOR)-related non-infectious pneumonitis: a potential biomarker of clinical benefit?
    Rodriguez-Vida A; Chau NM; Chowdhury S
    BJU Int; 2014 Mar; 113(3):350-1. PubMed ID: 24528875
    [No Abstract]   [Full Text] [Related]  

  • 19. One decade of improving palliative care of metastatic renal cell carcinoma by antiangiogenic therapies: time to move toward RCC cure.
    Kroeger N; Zimmermann U; Burchardt M
    Int J Cancer; 2015 Apr; 136(7):1483-4. PubMed ID: 25230294
    [No Abstract]   [Full Text] [Related]  

  • 20. Subcutaneous fat necrosis due to molecular-targeted therapy.
    Ogari K; Arakawa Y; Cho Z; Wada M; Takenaka H; Katoh N; Asai J
    J Dermatol; 2017 Mar; 44(3):e7-e8. PubMed ID: 27374634
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.